Anatomical and Functional Outcomes in Delayed Onset versus Concurrent Retinal Detachment in Endophthalmitis.

Purpose: To determine the functional and anatomical outcomes of patients with endophthalmitis with concurrent or delayed onset retinal detachment (RD), and compare the preoperative, intraoperative and postoperative features. Patients and Methods: This was a retrospective review of 121 eyes in 121 patients presenting with endophthalmitis and RD. Subjects were categorized into two groups: endophthalmitis with delayed onset RD (group 1, N=76) and endophthalmitis with concurrent RD (group 2, N=45). Results: The mean age of patients in groups 1 and 2 was 38.21±21.60 and 46.78±24.42 years, respectively (P=0.047). Exogenous endophthalmitis was common in both groups 1 and 2 (86.84% and 84.44%, respectively). No significant differences were found between the groups in the type of RD, retinal breaks, number of quadrants involved or proliferative vitreoretinopathy grade. In the overall cohort, visual acuity improved post-surgery in one-third of the patients who were in the near or total blindness category at presentation. We found good anatomical success rates of an attached retina in both groups 1 and 2 (84.3% and 77.7%, P=0.376). Conclusion: Our study presents the results of patients with endophthalmitis and delayed onset RD or concurrent RD. It shows a few differences in presentation between the groups, but the anatomical and functional outcomes were almost the same.

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation.

INTRODUCTION: To analyze the efficacy of biosimilar ranibizumab compared to innovator ranibizumab and bevacizumab. METHODS: We retrospectively analyzed consecutive patients treated with biosimilar ranibizumab for wet age-related macular degeneration (AMD) and macular edema (ME) (due to diabetes and vein occlusion) and compared them with ranibizumab- and bevacizumab-treated patients. RESULTS: Of 202 patients, 67 (33.2%) received biosimilar ranibizumab (BSR), 69 (34.2%) ranibizumab (RBZ) and 66 (32.7%) bevacizumab (BEV). All patients received three consecutive injections followed by pro re nata dosing. The follow-up ranged from 3 to 24 months. The mean numbers of injections were 6.68 for RBZ, 6.4 for BEV and 4.7 for BSR. At 3 months, nAMD (n = 115, 56.9%) and ME (n = 87, 43.1%) groups showed significant improvement in vision and central foveal thickness (CFT) across all three agents. After ≥ 6 months, the effects were maintained in the AMD group but not in the ME group. Maximum effect was seen at 1 month. At no point in time was a significant difference noted among the three anti-vascular endothelial growth factor (anti-VEGF) agents. No major safety concerns were noted. CONCLUSIONS: Biosimilar ranibizumab is comparable to innovator ranibizumab and bevacizumab in efficacy and safety.